XVIVO — Xvivo Perfusion AB Cashflow Statement
0.000.00%
- SEK9.54bn
- SEK9.26bn
- SEK822.42m
Annual cashflow statement for Xvivo Perfusion AB, fiscal year end - December 31st, SEK millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Net Income/Starting Line | -57.3 | 6.67 | 22.3 | 94.5 | 200 |
Depreciation | |||||
Non-Cash Items | 49.4 | 7.2 | -14.7 | -78.3 | -87 |
Unusual Items | |||||
Other Non-Cash Items | |||||
Changes in Working Capital | -4.36 | -25.9 | -22 | -46.2 | -89.4 |
Change in Accounts Receivable | |||||
Change in Inventories | |||||
Change in Accounts Payable | |||||
Other Operating Cash Flow | |||||
Cash from Operating Activities | -12.3 | -12.1 | 27.9 | 46.3 | 111 |
Capital Expenditures | -64.7 | -94.1 | -131 | -144 | -193 |
Purchase of Fixed Assets | |||||
Purchase / Acquisition of Intangibles | |||||
Other Investing Cash Flow Items | -202 | -93.6 | -66.7 | -17.7 | -50.7 |
Acquisition of Business | |||||
Sale of Fixed Assets | |||||
Sale/Maturity of Investment | |||||
Purchase of Investments | |||||
Cash from Investing Activities | -267 | -188 | -198 | -162 | -244 |
Net Issuance / Retirement of Stock | |||||
Net Issuance / Retirement of Debt | |||||
Cash from Financing Activities | 483 | 235 | -6.84 | 419 | -10.9 |
Foreign Exchange Effects | |||||
Beginning Cash Balance | |||||
Ending Cash Balance | |||||
Net Change in Cash | 194 | 44.5 | -152 | 300 | -131 |